PARAMOUNT trial: Reopening a window to maintenance therapy

Journal of Clinical Oncology

Volumn 32, Issue 5, 2014, Pages 480-481

  Barni, Sandro ^a   Petrelli, Fausto ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; NOTE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE;

EID: 84897573118     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.9875     Document Type: Letter

References (8)

1. Paz-Ares LG, de Marinis F, Dediu M, et al: PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31:2895-2902, 2013
2. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
3. Brodowicz T, Krzakowski M, Zwitter M, et al: Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer 52:155-163, 2006
4. Pérol M, Chouaid C, Pérol D, et al: Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 30:3516-3524, 2012
5. Cai H, Lin Y, Li W, et al: Maintenance treatment with different strategies in advanced non-small-cell lung cancer: A systematic review and meta-analysis. Clin Lung Cancer 14:333-341, 2013
6. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004 (Pubitemid 41079796)
7. Hotta K, Suzuki E, Di Maio M, et al: Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer 79:20-26, 2013
8. Hayashi H, Okamoto I, Morita S, et al: Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Ann Oncol 23:1537-1541, 2012